Mizuho Discusses Biogen (BIIB) Seizure Patient

Mizuho analyst Salim Syed discussed Biogen (NASDAQ: BIIB) Aducanumab's LTE seizure patient, which has the stock well off highs (+0.4%).

"On the seizure patient, we spoke to the company (they weren't willing to say much beyond the slide) ... this is a new potential safety issue though for the drug in our opinion that we need to learn more about," he commented.

Here is what we know for now:

1. There was one patient that suffered a seizure. This patient also had ARIA. Recall, this was a relatively small study, so the question here is if we should be expecting to see more in the Phase 3 study

2. Given the seizure occurred in a new ARIA case, and ARIA occurs early on drug, it was likely in a switcher in our view (company wasn't willing to confirm)

You May Also Be Interested In

• Biogen (BIIB) PT Raised to $260 at RBC Capital, 'Deep Dive Suggests Upcoming Liti SLE Data Could Start I&I Buildout On Right Path'
• NVIDIA (NVDA) PT Raised to $346 at Truist Securities
• Okta, Inc (OKTA) PT Raised to $143 at Bernstein SocGen Group